Research – E.W. Scripps (SSP) – Differentiated From Its Peers

Wednesday, August 28, 2019

E.W. Scripps (SSP)

Differentiated From Its Peers

The E.W. Scripps Company serves audiences and businesses through a growing portfolio of media brands. Scripps currently has 34 radio stations and will expand to over 50 stations with recently announced acquisitions. In addition to its Television station portfolio, SSP runs an expanding collection of national businesses, including podcasting content and infrastructure, a cable network and digital news business, and national broadcast networks.

Michael Kupinski, Senior Research Analyst, DOR, Noble Capital Markets, Inc.

Refer to full report for price target, fundamental analysis and rating.

  • Non-deal road show highlights. This report provides notes from a recent investor marketing trip with CFO, Lisa Knutson, and Corporate Communications and IR, Carolyn Micheli.
  • Separating itself from its high debt leveraged rivals. The company has a unique and clear path toward deleveraging it balance sheet due to a significant increase in…



    Get full report on Channelchek desktop.


*Analyst
certification and important disclosures included in full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision.
 

Research – Trovagene (TROV) – Progressing Prostate Cancer Data in Small Number of Patients

Tuesday, August 27, 2019

Trovagene Inc. (TROV)

Progressing Prostate Cancer Data in Small Number of Patients

TrovaGene Inc is a US-based life science company which focuses on the development and commercialization of a proprietary molecular genetic detection technology for use in pharmaceutical development, clinical research and medical testing across a variety of clinical disciplines, including oncology and virology.

Ahu Demir, Ph.D., Biotechnology Research Analyst, Noble Capital Markets, Inc.

Refer to full report for price target, fundamental analysis and rating.

  • Data presentation at APCC.   Trovagene presented data from the Phase 2 Study of
    Onvansertib in combination with Zytiga in patients with metastatic castration-resistant prostate cancer (mCRPC) at the 20th Asia-Pacific Prostate Cancer Conference. The data showed that two out of the four patients who tested positive for androgen receptor splice variant 7 (AR-V7) achieved the primary endpoint of disease control. As presented in ASCO, AR-V7 has been associated with poor prognosis and hormone therapy resistance in mCRPC patients (based on results from a prospective-blinded study (PROPHECY).
  • Still early to speculate clinical benefit.  We believe it is still early to speculate
    Onvansertib’s clinical efficacy in patients with mCRPC. We recognize the strong…



    Get full report on Channelchek desktop.


This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision.
 

Pharma Mergers and Acquisitions: Who’s Really Winning Here?

Pharma Mergers and Acquisitions: Who’s Really Winning Here?

(Note: companies that could be impacted by the content of this article are listed at the base of the story (desktop version). This article uses third-party references to provide a bullish, bearish and balanced point of view; sources listed in the “Balanced” section)

The Big Pharma companies in the game including Pfizer Inc., Novartis, and Johnson & Johnson seem to enjoy M&A deals, specifically with small cap biotech stocks. The pharmaceutical giants acquire smaller companies that have patents or technological advancements that they are lacking. Most of these small companies that are acquired do not have sufficient capital to sustain long-term growth. Therefore, mergers and acquisitions deals are important for pharma company growth, but can too many mergers harm the environment in which they operate?

Will the Uncertain Economy Boost Mining Stocks?

Will the Uncertain Economy Boost Mining Stocks?

(Note: companies that could be impacted by the content of this article are listed at the base of the story (desktop version). This article uses third-party references to provide a bullish, bearish and balanced point of view; sources listed in the “Balanced” section)

The history of gold dates back to 3000 B.C. when the ancient Egyptians started using the material to form jewelry, but it was not until 560 B.C. that it was used as a currency. Since then the purpose for gold has diminished, yet the majority of investors still hold some form of it in their portfolio. They have the option of holding the actual commodity, buying stock in gold mining companies or investing through exchange-traded funds. The importance of gold goes back to the fact that is has preserved wealth throughout thousands of generations. When investors face a declining U.S. dollar and rising inflation, the idea of the resource holding onto its value becomes even more important. Resulting from recent trade tensions, gold prices rally, pushing it towards a new six-year high.

NNW News – Entrepreneurs Tips To Take Gig Work To The Next Level

Entrepreneurs’ Tips To Take Gig Work To The Next Level

ATLANTA, Aug. 27, 2019 /PRNewswire/ — Eighty-one percent of Americans who currently have a side gig are interested in taking it full-time, according to a recent SunTrust survey. More than half of Americans (54%) report having a side hustle at some point to generate extra money, pulling in $8,794, on average per year. With these additional funds, people are able to pursue their  #bestlife on their own terms.

On average, millennials are making almost 20% more per year ($10,972) from their side hustles than Gen Xers ($8,791) and 46% more than Boomers ($5,892). The top reason for pursuing a side hustle among millennials is to generate additional income for saving purposes (46%), while the top reason among Gen Xers and Boomers is to make additional money for leisure activities (43% and 47%).

“There’s a reason the gig economy is so hot – it can be fun and financially fruitful,” said Brian Ford, financial well-being executive at SunTrust. “For some, a side hustle is a creative outlet outside of the daily grind. For many others, it’s a means to achieving the financial confidence and freedom to live life on their own terms. Whether the goal is to earn extra cash or take a side gig full-time, there are tools and services to help people propel their side hustle forward.”

So, what gets in the way of taking a fringe earning situation full time?

The overwhelming majority of those looking to make their side hustle their main gig (83%) face obstacles, from not having enough time to dedicate to it (36%) to not having enough financial capital (30%).

SunTrust offers the following tips to help would-be full time entrepreneurs make the grade in the school of side hustle:

  • Time the Tipping Point: Determine when it is best to take a side hustle full time by weighing the trade-off of investing more time on your side gig versus your primary income source. Be mindful of the opportunity cost of sacrificing the stability of your total compensation package for unpredictable earnings potential.
  • Focus on the Fund-amentals: Make sure to develop an initial business plan, goals and competitive strategy, and decide how to fund your business and pay yourself. You’ll also want to include business cash projections and their reliability along with other funding sources.
  • Study the Setup: Determine the best legal structure for your business in conjunction with business advisors, such as an attorney and CPA. You’ll also want to understand regulatory issues in your industry, file appropriate permits and licenses and register your business and domain name.
  • Build a Budget: Develop a budget and use it to regularly track your progress against planned revenues and expenditures. A budget will also allow you to view financial priorities and targets and measure actual business performance against projections. These types of guardrails are critical when you are busy, and cash-on-hand can’t absorb cost overruns.
  • Track Your Finances: Separate personal and business finances with a business checking account. Set up online and mobile bank account access to monitor your daily cash position, pay bills and make easy transfers.
  • Bank on Bookkeeping: Set up financial software to establish good bookkeeping habits and automate recordkeeping. Considering linking your business checking account and your financial software so you can easily record income and expenses, track receivables, pay bills and manage inventory.
  • Work the Perks: Use credit or purchasing cards for expenses. Business credit cards offer tools to easily identify costs and manage employee spending limits and track usage. Online account access provides greater visibility into daily spending, and some cards even offer reward points or cash back on certain transactions.
  • Set Up for Sales: Ramp up revenue faster than costs and expenses by focusing on actions that have the greatest impact on sales and building a customer base during the crucial early days.

SunTrust recently introduced its 21-day #bestlifechallenge, a social campaign to help people get on track toward achieving the financial confidence to live their dreams.

“As someone who took my photography side hustle into a full-time career, I knew that confidence in myself, my craft and my finances would be pivotal in this big decision to start my own business,” said Evan Ranft, a professional photographer based in Atlanta. “Participating in the #bestlifechallenge has allowed me to take a closer look at smarter ways to budget so that I can live my best life on my own terms, whether I’m saving up for a new camera lens or crossing a new destination off of my travel bucket list.”

For resources to help take your side hustle to the next level, visit SunTrust’s Small Business Best Practices site. You can also level up your financial confidence by joining the #bestlifechallenge at onup.com.

Survey
Methodology

This survey was conducted online within the United States by The Harris Poll on behalf of SunTrust from July 16 – 18, 2019 among 2,028 U.S. adults ages 18 and older, among whom 1,116 ever had a side hustle. The survey defines millennials as those age 23-38, Gen Xers age 39-54 and Boomers age 55-73. This online survey is not based on a probability sample and therefore no estimate of theoretical sampling error can be calculated.

About
SunTrust Banks, Inc.

SunTrust Banks, Inc. (NYSE: STI) is a purpose-driven company dedicated to Lighting the Way to Financial Well-Being for the people, businesses, and communities it serves. SunTrust leads onUp, a national movement inspiring Americans to build financial confidence. Headquartered in Atlanta, the Company has two business segments: Consumer and Wholesale. Its flagship subsidiary, SunTrust Bank, operates an extensive branch and ATM network throughout the high-growth Southeast and Mid-Atlantic states, along with 24-hour digital access. Certain business lines serve consumer, commercial, corporate, and institutional clients nationally. As of June 30, 2019, SunTrust had total assets of $222 billion and total deposits of $161 billion. The Company provides deposit, credit, trust, investment, mortgage, asset management, securities brokerage, and capital market services. Learn more at suntrust.com.

Cision View original content:http://www.prnewswire.com/news-releases/suntrust-survey-many-americans-interested-in-taking-their-side-gigs-full-time-300907711.html

SOURCE SunTrust Banks, Inc.

Source: PR Newswire (August 27, 2019 – 9:53 AM EDT) 

NNW News – Genprex Inc. (GNPX) Making Headway in Clinical Program Expansion, Company Growth

Genprex Inc. (GNPX) Making Headway in Clinical Program Expansion, Company Growth


Related Editorial
Biotech and biopharma industry leaders are posting record financials and hitting milestone markers in their research and growth, good indicators of a strong market with potential for robust returns on investment.

Genprex Inc. (NASDAQ: GNPX) (GNPX Profile) has completed key steps in its overall strategy to expand its clinical development programs and bring Oncoprex(TM) immunogene therapy, its lead drug candidate, to commercialization. Over the past five years, Amgen Inc. (NASDAQ: AMGN) has invested nearly $19 billion in R&D and, as a result, is now advancing a record number of clinical assets. Biogen Inc. (NASDAQ: BIIB) has added four new programs to its pipeline this quarter alone as the company continues to diversify and build depth within neuroscience and pursue therapeutic adjacencies. Celgene Corporation (NASDAQ: CELG) announced recently that its stockholders voted to approve the company’s proposed combination with Bristol-Myers Squibb Company (NYSE: BMY). This key milestone brings the two complementary biopharmaceutical companies one step closer to combining their efforts on a shared mission of discovering, developing and delivering innovative medicines for patients with serious diseases.

To view the full editorial, visit http://nnw.fm/jfD6C

About Genprex, Inc.

Genprex, Inc. is a clinical stage gene therapy company developing potentially life-changing technologies for cancer patients, based upon a unique proprietary technology platform, including Genprex’s initial product candidate, Oncoprex(TM) immunogene therapy for non-small cell lung cancer (NSCLC). Genprex’s platform technologies are designed to administer cancer fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. Oncoprex has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis, or programmed cell death, in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance. For more information, visit the company’s website at www.Genprex.com.

NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://nnw.fm/GNPX

About NetworkNewsAudio

NetworkNewsAudio, a service of NetworkNewsWire
(NNW)
, allows you to sit back and listen to market updates, interviews and company press releases. NetworkNewsAudio keeps you informed on publicly traded companies we’re watching. The audio clips provide snapshots of position, opportunity and momentum. NetworkNewsAudio is a Brand Awareness Distribution Solution from NetworkNewsWire.

For more information, visit www.NetworkNewsAudio.com

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
[email protected]

Trovagene Presents Positive Clinical Data from Ongoing Phase 2 Study of Onvansertib in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Trovagene Presents Positive Clinical Data from Ongoing Phase 2 Study of Onvansertib in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

  • Trial leads to discovery that onvansertib stops rise in PSA in patients with treatment-resistant, highly-aggressive and difficult-to-treat androgen-receptor variant 7 (AR-V7) tumors
  • Data demonstrates efficacy of onvansertib in patients showing early signs of resistance to androgen receptor signaling (ARS) inhibitor, Zytiga®
  • Addition of onvansertib appears to extend the duration of response to ARS inhibitor therapy in this incurable and lethal cancer

SAN DIEGO, Aug. 26, 2019 /PRNewswire/ — 
Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, Precision Cancer Medicine™ oncology therapeutics company developing drugs that target cell division (mitosis), for the treatment of various cancers including prostate, colorectal and leukemia, today announced the presentation of positive clinical data from its ongoing Phase 2 clinical trial of onvansertib in combination with Zytiga® (abiraterone acetate)/prednisone, an androgen-receptor signaling (ARS) inhibitor, in metastatic Castration-Resistant Prostate Cancer (mCRPC), at the 20th Asia-Pacific Prostate Cancer Conference in Melbourne, Australia. These data demonstrate the efficacy of onvansertib in patients showing resistance to the ARS inhibitor, Zytiga® (Johnson & Johnson), including those with the highly-aggressive and difficult-to-treat androgen receptor variant 7 (AR-V7) tumor.

Trovagene is a clinical-stage oncology therapeutics company, using a precision medicine predictive biomarker approach to develop drugs that target cell division (mitosis) for the treatment of leukemias, lymphomas and solid tumor cancers. Onvansertib, its lead drug candidate, is a first-in-class, 3rd generation, highly-selective oral Polo-like Kinase 1 (PLK1) Inhibitor.  The Company currently has two ongoing open-label clinical trials: a Phase 1b/2 trial in acute myeloid leukemia (AML) and a Phase 2 trial in metastatic castration-resistant prostate cancer (mCRPC).

“We have discovered that adding onvansertib to daily ARS inhibitor therapy changes the trajectory of resistance in patients harboring AR-V7, as demonstrated by the immediate decrease in serum PSA levels in patients showing initial signs of resistance to Zytiga®,” said Mark Erlander, PhD, Chief Scientific Officer of Trovagene. “The inhibition of the PLK1 enzyme by onvansertib appears to enhance the efficacy of Zytiga® by repressing the ARS pathway, which is consistent with preclinical data.”

In the ongoing Phase 2 clinical trial of onvansertib, a first-in-class, oral and highly-selective PLK1 inhibitor, patients are being tested with a simple blood test to assess whether they are positive for AR-V7.  In all four patients who tested positive for AR-V7, thus far, an immediate decrease in their serum PSA levels was observed. To-date, two of these patients have achieved the primary efficacy endpoint of disease control. Importantly, while on Zytiga® alone the PSA level for one of the AR-V7 positive patients had a greater than five-fold rise in the two months prior to enrollment and treatment in the trial. Once onvansertib was added to Zytiga®, the patient’s PSA level stopped rising and immediately decreased; the patient remains on treatment.

Additionally, since presenting early data at the American Association for Cancer Research in April, a second arm (Arm B) with a two-week dosing schedule and 50% greater drug exposure to onvansertib over the treatment course, was added to the trial. Preliminary efficacy with PSA stabilization or reduction was observed in the initial three patients enrolled, suggesting that a shorter dosing schedule may maximize response to treatment. Importantly, no unexpected, off-target toxicities have been reported in patients treated to-date.

mCRPC is an incurable and lethal cancer. Nearly all patients with prostate cancer will progress to castration resistance, indicated by increasing serum PSA levels despite castrate levels of testosterone and progress to metastases. 10% to 20% of prostate cancers progress to castration resistant prostate cancer (CRPC) within 5 years of diagnosis, and 84% of newly diagnosed CRPC have metastases. The median survival of patients following diagnosis of castration resistance ranges between 15 and 36 months. The standard-of-care first-line treatment are ARS inhibitors, Zytiga® (Johnson & Johnson) or Xtandi® (Pfizer); however, resistance to these drugs typically develops within 9 to 15 months of initiating treatment. Additionally, up to 30% of patients have the highly-aggressive and ARS-resistant AR-V7. These patients have a shorter progression-free survival (PFS), overall survival (OS) and a poor prognosis. Current treatment for these patients is limited to toxic chemotherapy and there are no effective targeted therapies available.

About Onvansertib

Onvansertib is a first-in-class, third-generation, oral and highly-selective adenosine triphosphate (ATP) competitive inhibitor of the serine/threonine polo-like-kinase 1 (PLK1) enzyme, which is over-expressed in multiple cancers including leukemias, lymphomas and solid tumors. Onvansertib targets the PLK1 isoform only (not PLK2 or PLK3), is orally administered and has a 24-hour half-life with only mild-to-moderate side effects reported. Trovagene believes that targeting only PLK1 and having a favorable safety and tolerability profile, along with an improved dose/scheduling regimen will significantly improve on the outcome observed in previous studies with a former panPLK inhibitor in AML.

Onvansertib has demonstrated synergy in preclinical studies with numerous chemotherapies and targeted therapeutics used to treat leukemias, lymphomas and solid tumor cancers, including irinotecan, FLT3 and HDAC inhibitors, taxanes and cytotoxins. Trovagene believes the combination of onvansertib with other compounds has the potential to improve clinical efficacy in acute myeloid leukemia (AML), metastatic castration-resistant prostate cancer (mCRPC), non-Hodgkin lymphoma (NHL), colorectal cancer and triple-negative breast cancer (TNBC), as well as other types of cancer.

Trovagene has an ongoing Phase 2 clinical trial of onvansertib in combination with Zytiga® (abiraterone acetate)/prednisone in patients with mCRPC who are showing signs of early progressive disease (rise in PSA but minimally symptomatic or asymptomatic) while currently receiving Zytiga®. The trial was accepted by the NLM and is now posted to www.clinicaltrials.gov, with a NCT number of NCT03414034.

Trovagene has an ongoing Phase 1b/2 Study of onvansertib in combination with FOLFIRI and Avastin® for second-line treatment in patients with mCRC with a KRAS mutation. The trial was accepted by the NLM and is now posted to www.clinicaltrials.gov, with a NCT number of NCT03829410. The trial is being conducted at three prestigious cancer centers: USC Norris Comprehensive Cancer Center, Hoag Cancer Center and The Mayo Clinic.

Trovagene has an ongoing Phase 1b/2 clinical trial of onvansertib in combination with low-dose cytarabine or decitabine in patients with relapsed or refractory AML that was accepted by the National Library of Medicine (NLM) and is now posted to www.clinicaltrials.gov, with a NCT number of NCT03303339. Onvansertib has been granted orphan drug designation by the FDA in the U.S. and by the EC in the European Union for the treatment of patients with AML. 

Trovagene licensed onvansertib (also known as NMS-1286937 and PCM-075) from Nerviano Medical Sciences (NMS), the largest oncology-focused research and development company in Italy, and a leader in protein kinase drug development. NMS has an excellent track record of licensing innovative drugs to pharma/biotech companies, including Array (recently acquired by Pfizer), Ignyta (acquired by Roche) and Genentech.

About Trovagene, Inc.

Trovagene is a a clinical-stage, Precision Cancer Medicine™ oncology therapeutics company developing drugs that target cell division (mitosis), for the treatment of various cancers including leukemias, lymphomas and solid tumors. Trovagene has intellectual property and proprietary technology that enables the Company to analyze circulating tumor DNA (ctDNA) and clinically actionable markers to identify patients most likely to respond to specific cancer therapies. Trovagene plans to continue to vertically integrate its tumor genomics technology with the development of targeted cancer therapeutics.  For more information, please visit 
https://www.trovageneoncology.com.

Forward-Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of words such as “anticipate,” “believe,” “forecast,” “estimated” and “intend” or other similar terms or expressions that concern Trovagene’s expectations, strategy, plans or intentions. These forward-looking statements are based on Trovagene’s current expectations and actual results could differ materially.  There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements.  These factors include, but are not limited to, our need for additional financing; our ability to continue as a going concern; clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; our clinical trials may be suspended or discontinued due to unexpected side effects or other safety risks that could preclude approval of our product candidates; uncertainties of government or third party payer reimbursement; dependence on key personnel; limited experience in marketing and sales; substantial competition; uncertainties of patent protection and litigation; dependence upon third parties; our ability to develop tests, kits and systems and the success of those products; regulatory, financial and business risks related to our international expansion and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. There are no guarantees that any of our technology or products will be utilized or prove to be commercially successful.  Additionally, there are no guarantees that future clinical trials will be completed or successful or that any precision medicine therapeutics will receive regulatory approval for any indication or prove to be commercially successful. Investors should read the risk factors set forth in Trovagene’s Form 10-K for the year ended December 31, 2018, and other periodic reports filed with the Securities and Exchange Commission.  While the list of factors presented here is considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Forward-looking statements included herein are made as of the date hereof, and Trovagene does not undertake any obligation to update publicly such statements to reflect subsequent events or circumstances.

Trovagene Contact: 
Vicki Kelemen 
VP, Clinical Development and Investor Relations 
858-952-7652 

[email protected] 

CisionView original content to download multimedia:http://www.prnewswire.com/news-releases/trovagene-presents-positive-clinical-data-from-ongoing-phase-2-study-of-onvansertib-in-metastatic-castration-resistant-prostate-cancer-mcrpc-300906644.html

SOURCE Trovagene, Inc.

News Provided by PR Newswire via QuoteMedia

What If Yields Turn Negative?

Inverted yield curve? So what! What if yields turn negative?

(Note: companies that could be impacted by the content of this article are listed at the base of the story (desktop version). This article uses third-party references to provide a bullish, bearish and balanced point of view; sources listed in the “Balanced” section)

The Dow Jones Industrial fell more than 800 points on August 14
th when the yield on the 10-year treasury bond fell below that of the 2-year treasury note.  Much has been made about the inversion of the yield curve and how that often signals a recession.  Less has been made about the fact that the government bond yields are now below 2% and appear to be headed lower.  Prominent bond experts such as Mohamed El-Erian and Alan Greenspan say they would not be surprised to see rates go negative.  The reason for the decline is obvious.  Investors are losing confidence in the economy and moving money from the stock market to places of security.  Will this lack of confidence become a self-fulfilling prophesy as decreased investment and spending cause economic weakness (bear case) or is it a mere coincidence (bull case)?

Research – Aurania Resources (ARU.V) – A Growing Number of Targets

Tuesday, August 13, 2019

Aurania Resources (ARU.V)

Gaining Momentum

Aurania Resources Ltd. is a junior mining exploration company engaged in the identification, evaluation, acquisition, and exploration of mineral property interests, with a focus on precious metals and copper. Its flagship asset, The Lost Cities – Cutucu Project, is in southeastern Ecuador in the Province of Morona-Santiago. The project includes 42 mineral exploration concessions encompassing an area of approximately 208,000 hectares, or 2,080 square kilometers. The company’s common shares are traded on the TSX Venture Exchange under the symbol “ARU”, the OTCQB Venture Market under the symbol “AUIAF” and on the Frankfurt Exchange under the symbol “20Q”.

Mark Reichman, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to full report for price target, fundamental analysis and rating.

  • Scout drilling to begin in mid-September.  Aurania Resources recently provided an update on its planned drilling program at Yawi, where four of its seventeen gold and silver targets are located within the Lost Cities project area. Management expects all permits, including scout drilling and water permits, to be in place for drilling to begin on the first of the Yawi targets in mid-September 2019.
  • Growing list of gold and silver targets.   The most recent addition to the target list is “Apai”, an epithermal target located near the southern boundary of the project. Aurania recently engaged Metron, Incorporated to…



    Get full report on Channelchek desktop.


This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision.
 

Research – 1-800-Flowers.com (FLWS) – Why this quarter stands out.

Friday, August 23, 2019

1-800-Flowers.com (FLWS)

Setting Expectations That Can Be Beat

1-800-FLOWERS.COM, Inc. is the leading provider of gourmet and floral gifts for all occasions. For nearly 40 years, 1-800-FLOWERS® has been helping deliver smiles for customers with gifts for every occasion, including fresh flowers, premium, gift-quality fruits and other gourmet items from Harry & David®, popcorn and specialty treats from The Popcorn Factory®; cookies and baked gifts from Cheryl’s®; premium chocolates and confections from Fannie May®; gift baskets and towers from 1-800-Baskets.com®; premium English muffins and other breakfast treats from Wolferman’s; carved fresh fruit arrangements from FruitBouquets.com; and top quality steaks and chops from Stock Yards®. The Company’s BloomNet® international floral wire service provides a broad range of quality products and value-added services designed to help professional florists grow their businesses profitably.

Michael Kupinski, Senior Research Analyst, DOR, Noble Capital Markets, Inc.

Refer to full report for price target, fundamental analysis and rating.

  • Solid quarter. Overachieves revenue expectations, while meeting our adj. EBITDA (cash flow) estimates. Total company revenues were $259.4 mil. versus our $251.9 mil. estimate. The largest upside variance was in Gourmet Food, $72.5 mil. versus our $66.5 mil. estimate, which benefited from strong underlying 7% revenue growth and a bump from Easter. Adj. EBITDA loss of $2.7 mil. was on target.
  • Why the quarter stands out.   We would note that the company had a solid quarter in spite of an incremental $2.5 mil. in compensation expenses year over year. Furthermore, with the acquisition of Shari’s Berries in August, the company is expected to…



    Get full report on Channelchek desktop.


This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision.
 

Will Iran Continue to Grow Their Nuclear Program?

Will Iran Continue to Grow Their Nuclear Program?

(Note: companies that could be impacted by the content of this article are listed at the base of the story (desktop version). This article uses third-party references to provide a bullish, bearish and balanced point of view; sources listed in the “Balanced” section)

In 2015, Iran agreed to a long-term nuclear accord with six other world powers, called the Joint Comprehensive Plan of Action. It came after years of tension over Iran’s efforts to develop nuclear weapons, even though they insisted the program was entirely peaceful, the international community was not convinced. The other side of the deal consisted of lifting sanctions that were crippling Iran’s economy. It was set to last 15 years after the “implementation day” which took place January of 2016. In May 2018, President Donald Trump withdrew the United States from the agreement, stating it failed to address Iran’s ballistic missile program. He reimpose sanctions and is now moving to diminish Iran’s oil exports. Resulting from this, Iranian President Hassan Rouhani announced they will no longer adhere to certain limits as they have not seen the deal’s envisioned economic benefits.

Aurania Refines Its Newly Discovered Apai Gold-Silver Target in Southeastern Ecuador

Aurania Refines Its Newly Discovered Apai Gold-Silver Target in Southeastern Ecuador

Toronto, Ontario–(Newsfile Corp. – August 22, 2019) – Aurania Resources Ltd. (TSXV: ARU) (OTCQB: AUIAF) (FSE: 20Q) (“Aurania” or the “Company”) reports that further exploration has refined its Apai target for gold and silver in its Lost Cities – Cutucu Project (“Project”) in southeastern Ecuador. Furthermore, Apai is suspected to be linked geologically to the copper target that SolGold PLC (“SolGold”) has identified on its mineral concessions 10 kilometres (“km”) to the south.

Aurania’s Chairman and CEO commented, “We have now identified twenty epithermal systems in 50% of the area of the Lost Cities Cutucu Project that has been field-checked by our exploration team. We’re excited that we’re finding epithermals, that are prime gold and silver targets, aligned along fault corridors and potentially fed by porphyry systems, a relationship seen in clusters of deposits throughout the Pacific Rim. Our task is to use field characteristics and scout drilling to rank these targets for further focused exploration to create shareholder value.”

Apai Target

Recent field work has shown that the centre of the Apia target is marked by abundant sinter blocks over an area of at least 1.2km by 0.5km. Younger rocks partially cover the sinter, making it impossible to estimate its true size at present. Veins of opal and chalcedony that have been found in outcrop, and along with sinter, are common features of the top of epithermal systems. The highest arsenic values are found in a stream that drains the sinter, while the surrounding area that is 4.5 km long and 3km wide, contains elevated levels of this important pathfinder element for gold in epithermal systems. Naturally-occurring mercury has been identified over an area that is larger than the zone of arsenic enrichment, and encloses the opal and chalcedony veins as well as hydrothermal breccias (Figure 1). Streams in the Apai target area also contain elevated concentrations of silver and pathfinder elements including antimony, selenium and bismuth.

Possible Link to Adjacent Mineralization

Detailed interpretation of satellite imagery for Aurania by an independent consultant shows that the Apai epithermal target lies within the same fault system as the high-grade copper found in a breccia in SolGold’s “Anomaly 2” in its Coangos 2 concession (Figure 1). These targets may provide an example of the common relationship of epithermal gold-silver deposits lying along trend of porphyry copper-related deposits within fault-bounded corridors. Such linked deposits are believed to arise when hot, hydrothermal fluids responsible for copper mineralization in porphyries, rise and cool along fault corridors, depositing gold and silver in epithermal deposits. [Note that Aurania has not independently verified the results reported by SolGold and is relying on the information provided in SolGold’s press release issued on May 10, 2019].

Next Steps

  • Undertake soil sampling in the drainage basins in which elevated silver and pathfinder elements were detected in the stream sediment sampling program;
  • Undertake detailed alteration mapping – this is to detect the minerals that have developed from the reaction of hot, metal-bearing fluids with the host-rocks. These alteration minerals are typically arranged in a roughly concentric pattern around mineralized systems and provide a way of vectoring toward the heart of the system where the metals are located;
  • Geophysics will be considered; and
  • Application has been made for the water-use permit for scout drilling, which requires several steps:
    • Samples from streams from which water is to be pumped for scout drilling are undergoing repeated testing and analysis to establish a baseline for comparison with tests made at regular intervals during and after drilling. This work is necessary to demonstrate that there is no contamination of water from the drilling and serves to protect the Company against potential and unfounded allegations in the future;
    • The sites from which water is planned to be taken have been reviewed by an independent consultant who has verified that the streams would support the pumping of the 1.5 litres per second required for drilling, without significantly affecting flow levels; and
    • The above information has been included in an application for water-use that is being submitted to the controlling entity called SENAGUA.

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/2477/47158_20c232683425f896_001.jpg

Figure 1. Map showing the location of the sinter at the centre of the Apai target and the extent of naturally-occurring arsenic and mercury in stream sediments relative to the location of the copper mineralization reported by Solgold from its mineral concessions immediately south of Aurania’s Lost Cities – Cutucu Project.

To view an enhanced version of Figure 1, please visit:
https://orders.newsfilecorp.com/files/2477/47158_20c232683425f896_001full.jpg

Sample Analysis & Quality Assurance / Quality Control (“QAQC”)

The samples were prepared for analysis at ALS Global’s (“ALS”) lab in Quito, Ecuador. The stream sediment samples were wet-sieved through a 20 mesh (0.84mm) screen in the field and placed in cloth bags so that excess water could drain. The samples were transported from the field to Aurania’s field office in Macas, Ecuador and batched for delivery to ALS’s preparation lab in Quito for drying and screening at 80 mesh (0.18mm sieve aperture). 250g of the -80 mesh silt was pulverized to 85% passing 0.075mm, and was packaged by ALS for analysis.

ALS’s preparation lab in Quito sent the prepared samples to its analytical facility in Lima, Peru for analysis: a 0.5g split of the -80 mesh fraction of the stream silt underwent digestion with aqua regia and the liquid was analyzed for 48 elements by ICP-MS. Apart from being analyzed by ICP-MS, gold was also analyzed by fire assay with an ICP-AES finish.

ALS reported that the analyses had passed its internal QAQC tests. In addition, Aurania’s analysis of results from its QAQC samples showed the batches reported on above, lie within acceptable limits.

Qualified Person

The technical information contained in this news release has been verified and approved by Jean-Paul Pallier, MSc. Mr. Pallier is a designated EurGeol by the European Federation of Geologists and is a Qualified Person as defined by National Instrument 43-101, Standards of Disclosure for Mineral Projects of the Canadian Securities Administrators.

About Aurania

Aurania is a junior mineral exploration company engaged in the identification, evaluation, acquisition and exploration of mineral property interests, with a focus on precious metals and copper. Its flagship asset, The Lost Cities – Cutucu Project, is located in the Jurassic Metallogenic Belt in the eastern foothills of the Andes mountain range of southeastern Ecuador.

Information on Aurania and technical reports are available at www.aurania.com and www.sedar.com, as well as on Facebook at https://www.facebook.com/auranialtd/, Twitter at https://twitter.com/auranialtd, and LinkedIn at https://www.linkedin.com/company/aurania-resources-ltd-.

For further information, please contact:

Carolyn Muir
Manager – Investor Services
Aurania Resources Ltd.
(416) 367-3200
[email protected]

Dr. Richard Spencer
President
Aurania Resources Ltd.
(416) 367-3200
[email protected]

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release may contain forward-looking information that involves substantial known and unknown risks and uncertainties, most of which are beyond the control of Aurania. Forward-looking statements include estimates and statements that describe Aurania’s future plans, objectives or goals, including words to the effect that Aurania or its management expects a stated condition or result to occur. Forward-looking statements may be identified by such terms as “believes”, “anticipates”, “expects”, “estimates”, “may”, “could”, “would”, “will”, or “plan”. Since forward-looking statements are based on assumptions and address future events and conditions, by their very nature they involve inherent risks and uncertainties. Although these statements are based on information currently available to Aurania, Aurania provides no assurance that actual results will meet management’s expectations. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. Forward looking information in this news release includes, but is not limited to, Aurania’s objectives, goals or future plans, statements, exploration results, potential mineralization, the corporation’s portfolio, treasury, management team and enhanced capital markets profile, the estimation of mineral resources, exploration and mine development plans, timing of the commencement of operations and estimates of market conditions. Factors that could cause actual results to differ materially from such forward-looking information include, but are not limited to, failure to identify mineral resources, failure to convert estimated mineral resources to reserves, the inability to complete a feasibility study which recommends a production decision, the preliminary nature of metallurgical test results, delays in obtaining or failures to obtain required governmental, regulatory, environmental or other project approvals, political risks, inability to fulfill the duty to accommodate indigenous peoples, uncertainties relating to the availability and costs of financing needed in the future, changes in equity markets, inflation, changes in exchange rates, fluctuations in commodity prices, delays in the development of projects, capital and operating costs varying significantly from estimates and the other risks involved in the mineral exploration and development industry, and those risks set out in Aurania’s public documents filed on SEDAR. Although Aurania believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Aurania disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/47158

News Provided by Newsfile via QuoteMedia

The inverted yield curve: what does this really indicate?

The inverted yield curve: what does this really indicate?

(Note: companies that could be impacted by the content of this article are listed at the base of the story (desktop version). This article uses third-party references to provide a bullish, bearish and balanced point of view; sources listed in the “Balanced” section)

The news of an inverted yield curve has been lingering around market news headlines for days. For reference, an inverted yield curve occurs when long term rates are less than short term rates. It typically indicates that the chance of an economic recession in the future is high. With those headlines glooming over the average investor, it is important to know what the inverted U.S. yield curve represents, and what the warning signs indicate.